Kite Receives U.S. FDA Approval Of Manufacturing Process Change Resulting In Reduced Median Turnaround Time For Yescarta® CAR T-Cell Therapy

• Kelly Wilson
• January 30, 2024
• Drugs

(Gilead) Jan 30, 2024 – Kite, a Gilead Company, today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in the U.S. is anticipated to be reduced from 16 days to 14 days.